TABLE 1.
Participant characteristics1
| Study design | |||
|---|---|---|---|
| FA profile of RBC | Plasma | Urine | |
| membranes | metabolomics | metabolomics | |
| Variable | (n = 25) | (n = 10) | (n = 9) |
| Sex (F/M), n | 15/10 | 6/4 | 5/4 |
| Age group, n | |||
| Adults (≥18 y) | 25 | 8 | 6 |
| Adolescents (15–17 y) | 0 | 2 | 3 |
| Age, y | 29 ± 7 | 28 ± 10 | 25 ± 9 |
| Genotype, n | |||
| Classical PKU | 18 | 5 | 4 |
| Variant PKU | 7 | 5 | 5 |
| Sapropterin dihydrochloride use, n | 3 | 1 | 2 |
| BMI, kg/m2 | 26.2 ± 4.7 | 27.3 ± 5.8 | 25.8 ± 3.9 |
| Plasma Phe, µmol/L | 703 ± 295 | 635 ± 288 | 722 ± 257 |
| Plasma glucose, mg/dL | 84 ± 8 | 86 ± 9 | 87 ± 9 |
1Values are means ± SDs unless otherwise indicated. Information on participant characteristics shown here was obtained during visit 1 of the previously reported clinical trial (23). PKU, phenylketonuria.